I think Drs. Mullen and Chapman gave us some tidbits of what the plan is going forward. Clearly an IND application is well underway and will be filed within 3 months and Dr. Chapman felt very confident that the FDA would give the go ahead to start Phase 1. Dr Chapman felt very confident that Phase 1 would be fine and approved by the FDA. We know that Alzheimers will not be the disease targeted, at this time, in Phases 2 and 3, due to the significant cost and time requirements. There was lots of talk about Hashimoto's disease, Crohne's disease and MS. It has to be for one of those disorders. I believe they already know which one has been chosen but would not say what it is at this time. They can't file an IND without knowing what they are going to study.That would be asinine.
DR. Mullen spoke allot about how anatabine is beneficial with peripheral nerve problems and showed the mice with rear legs working/not working and Dr.Paris of Roskamp has done studies in this area... but then again the Thyroid results are already shown to be very good. Therefore, I'm guessing Thyroid only because there already has been a human study that showed good results.
When asked if they already had pre-liminary talks with a pharma company about partnering or teaming Dr.Mullen said he could not answer or could not discuss it. Would the temporary shift from Alzheimer's to some other disease signal that there is a partner who is not willing to invest in an Alzheimer study but is interested and willing to proceed with another disease for starters? We have to wait and see.
IMO, Drs.Chapman and Mullen were very calm and confident but seemed a little anxious as if they were not hiding something; but rather were sitting on something that they wanted to talk about but couldn't. Did anyone else get that impression?
AI
Market Data 
Markets 
